Effects of atorvastatin on bone metabolism and bone mineral density in Wistar rats

Pharmazie

Volumn 66, Issue 7, 2011, Pages 535-537

  Chang, Baocheng ^a   Yang, Juhong ^a   Li, Hechao ^a   Lu, Shan ^a   Chen, Liming ^a   Fang, Peihua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; CALCIUM; INTERLEUKIN 6; OSTEOCALCIN; PHOSPHORUS; BIOLOGICAL MARKER; CREATINE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; MALE; METABOLIC PARAMETERS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; RAT; TREATMENT RESPONSE; ANIMAL; BLOOD; BONE; BONE DEVELOPMENT; DOSE RESPONSE; METABOLISM; URINE; WISTAR RAT;

ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; CALCIUM; CREATINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; MALE; PHOSPHORUS; PYRROLES; RATS; RATS, WISTAR;

EID: 80051941066     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0826     Document Type: Article

References (23)

1. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR (2007) Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 92: 4671-4677. (Pubitemid 350223443)
2. Burridge K, Chrzanowska WM (1996) Focal adhesions, contractility, and signaling. Annu Rev Cell Dev Biol 12: 463-518.
3. Chuengsamarn S, Rattanamongkoulgul S, Suwanwalaikorn S, Wattanasirichaigoon S, Kaufman L (2010) Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46: 1011-1015.
4. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85: 1137-1142.
5. Hatzigeorgiou C, Jackson JL (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis, a meta-analysis. Osteoporos Int 16: 990-998. (Pubitemid 41127110)
6. Kawane T, Terashima S, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N (2004) Atorvastatin enhances bone density in ovariectomized rats given 17β-estradiol or human parathyroid hormone(1-34). Endocrine 24:121-129. (Pubitemid 41271163)
7. Kretz A, Schmeer C, Tausch S, Isenmann S (2006) Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol Dis 21: 421-430. (Pubitemid 43099865)
8. Laufs U, Liao JK (2000) Targeting rho in cardiovascular disease. Circ Res 87: 526-528.
9. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation, evidence from structure activity relationships in J774 macrophages. J Bone Miner Res 13: 1668-1678. (Pubitemid 28491995)
10. Luisetto G, Camozzi V (2009) Statins, fracture risk, and bone remodeling. J Endocrinol Invest 32: 32-37.
11. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21:1636-1641. (Pubitemid 34215584)
12. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283: 3205-3210. (Pubitemid 30422037)
13. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949. (Pubitemid 129515901)
14. Mundy G, Gutierrez G, Garret R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Robbins K, McKernan P, Gaspar S, Martinez T, West R, Durnam D (1998) Identification of a new class of powerful stimulators of new bone formation in vivo: clarification of mechanism of action, and use in animal models of osteoporosis. Bone 23: S183.
15. Ralston SH (1994) Analysis of gene expression in bone biopsies by polymerase chain reaction reaction, evidence of enhanced cytokine expression in post- menopausal osteoporosis. J Bone Miner Res 9: 883-885.
16. Tang QO, Tran GT, Gamie Z, Graham S, Tsialogiannis E, Tsiridis E, Linder T, Tsiridis E. (2008) Statins: under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin Investig Drugs 17: 1435-1463.
17. VanAelst L, DSouza-Schorey C (1997) Rho GTPases and signaling networks. Genes Dev 11: 2295-2322.
18. van Beek E, Löwik C, van der Pluijm G, Papapoulos S (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14: 722-729. (Pubitemid 29210598)
19. Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, Goto J, Yamamura M, Makino H (2008) Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rhomitogen- activated protein kinase pathway. J Endocrinol 196: 601-613. (Pubitemid 351425516)
20. Yang LC, Lan Y, Hu J, Yang YH, Zhang Q, Piao JH (2009) Correlation of serum leptin level with bone mineral density and bone turnover markers in Chinese adolescent dancers. Biomed Environ Sci 22: 369-373.
21. Yaturu S (2003) Skeletal effects of statins. Endocr Pract 9: 315-320.
22. Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269. (Pubitemid 26250610)
23. Zigmond SH (1996) Signal transduction and actin filament organization. Curr Opin Cell Biol 8: 66-73.